ArticleJournal of personalized medicine2015
Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue.
Article in Journal of personalized medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 27 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Light Emitting Diode for the Treatment of Genitourinary Syndrome of Menopause Associated With Hormonal Therapy for Treating Breast Cancer: Randomized Controlled Clinical Trial
Effectiveness of C02 Microfractionated Laser in Conjunction With Topical Regenerative Therapy in the Management of Vulvo-vaginal Atrophy in Patients With a History of Breast Cancer. Randomized Experimental and Comparative Study.
Who cites it
27 citing papers in PubMed, 4 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- Measuring serum oestrogen levels in breast cancer survivors using vaginal oestrogens: a systematic review.Breast cancer research and treatment · 2024Pooled it
- Pooled it
- Intravaginal energy-based devices and sexual health of female cancer survivors: a systematic review and meta-analysis.Lasers in medical science · 2020Pooled it
- Laser treatment for the management of genitourinary syndrome of menopause after breast cancer. Hope or hype?International urogynecology journal · 2019Pooled it
- Effects of sexual counseling and education based on self-efficacy theory on the sexual function of women with breast cancer.BMC women's health · 2025Trial
- The effect of vitamin D and E vaginal suppositories on tamoxifen-induced vaginal atrophy in women with breast cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019Trial
- Review
- Vaginal microbiome and inflammation cytokines among Chinese women.NPJ biofilms and microbiomes · 2026Article
- Vaginal aging: from concealed symptoms to defined biomarkers.npj aging · 2026Review
- Treating Genitourinary Syndrome of Menopause in Postmenopausal Women with a History of Breast Cancer.Drugs & aging · 2026Review
- Efficacy of Non-Invasive Monopolar Radiofrequency for Treating Genitourinary Syndrome of Menopause: A Prospective Pilot Study.Clinics and practice · 2025Article
- COCancers · 2025Article
- Genitourinary symptoms in women with breast cancer: frequency, severity and impact.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Vaginal health in breast cancer survivors: a practical clinical approach.Therapeutic advances in medical oncology · 2025Review
- Investigation ofFrontiers in pharmacology · 2025Article
- Vulvovaginal Atrophy Following Treatment for Oncogynecologic Pathologies: Etiology, Epidemiology, Diagnosis, and Treatment Options.Medicina (Kaunas, Lithuania) · 2024Review
- Herbal Treatment of Female Urogenital Atrophy: A Retrospective Cohort Analysis.Complementary medicine research · 2024Article
- Practical Guidance on the Use of Vaginal Laser Therapy: Focus on Genitourinary Syndrome and Other Symptoms.International journal of women's health · 2024Review
- Vaginal Laser Treatment for the Genitourinary Syndrome of Menopause in Breast Cancer Survivors: A Narrative Review.Cureus · 2023Review
- Emerging Use of Vaginal Laser to Treat Genitourinary Syndrome of Menopause for Breast Cancer Survivors: A Review.Medicina (Kaunas, Lithuania) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
Abstract
Management of breast cancer includes systematic therapies including chemotherapy and endocrine therapy can lead to a variety of symptoms that can impair the quality of life of many breast cancer survivors. Atrophic vaginitis, caused by decreased levels of circulating estrogen to urinary and vaginal receptors, is commonly experienced by this group. Chemotherapy induced ovarian failure and endocrine therapies including aromatase inhibitors and selective estrogen receptor modulators can trigger the onset of atrophic vaginitis or exacerbate existing symptoms. Symptoms of atrophic vaginitis include vaginal dryness, dyspareunia, and irritation of genital skin, pruritus, burning, vaginal discharge, and soreness. The diagnosis of atrophic vaginitis is confirmed through patient-reported symptoms and gynecological examination of external structures, introitus, and vaginal mucosa. Lifestyle modifications can be helpful but are usually insufficient to significantly improve symptoms. Non-hormonal vaginal therapies may provide additional relief by increasing vaginal moisture and fluid. Systemic estrogen therapy is contraindicated in breast cancer survivors. Continued investigations of various treatments for atrophic vaginitis are necessary. Local estrogen-based therapies, DHEA, testosterone, and pH-balanced gels continue to be evaluated in ongoing studies. Definitive results are needed pertaining to the safety of topical estrogens in breast cancer survivors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.